Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Gastric or GEJ Adenocarcinoma (Ahead-G201)
NCT02426034Phase 4Completed
- Sponsor
- Hengrui
- Start
- May 2015
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Rivoceranib in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Hengrui. Started May 2015; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02426034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426034.